Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$7.84
-0.8%
$6.75
$2.32
$10.13
$423.20M2.37911,117 shs357,213 shs
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
$0.71
-1.1%
$4.97
$0.24
$1.49
$10.56M2.82127,174 shs82,490 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.03
+15.4%
$0.03
$0.02
$0.14
$2.26M1.8993,204 shs26,100 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.85
+3.7%
$1.67
$1.15
$3.43
$12.90M-0.3422,154 shs11,675 shs
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$11.83
$11.83
$3.21
$18.22
$621.21M1.781.52 million shs1,084 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
+0.89%+12.54%+15.33%+159.87%-1.37%
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00%+10.82%-1.93%-60.98%-85.64%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-3.70%0.00%-3.70%-3.70%-81.75%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+2.59%+8.54%-2.47%+13.81%-47.49%
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
0.6189 of 5 stars
1.32.00.00.02.12.50.0
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.2417 of 5 stars
0.03.00.00.00.61.70.0
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.2349 of 5 stars
3.05.00.04.62.00.01.3
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
2.50
Moderate Buy$6.29-19.83% Downside
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
0.00
N/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00171.00% Upside
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest STML, GRTX, NERV, GEMP, and FULC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.00
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
5/23/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.00
5/15/2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$10.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
$80M5.29N/AN/A$4.51 per share1.74
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/A$0.54 per shareN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.23 per share8.04($3.67) per shareN/A
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
$43.22M14.37N/AN/A$3.26 per share3.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$9.73M-$0.07N/AN/AN/AN/A-0.20%-0.19%7/30/2025 (Estimated)
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
-$23.64MN/A0.00N/AN/A-419.70%-173.05%N/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$0.26N/AN/AN/AN/A-99.34%8/12/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.25N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
-$76.82M-$1.83N/AN/AN/A-150.30%-48.14%-41.35%N/A

Latest STML, GRTX, NERV, GEMP, and FULC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
5/1/2025Q1 2025
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
-$0.29-$0.28+$0.01-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/AN/AN/AN/AN/A
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
N/A
28.71
28.71
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
N/A
0.67
0.67
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
N/A
7.43
7.37
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
10053.98 million50.20 millionOptionable
Gemphire Therapeutics Inc stock logo
GEMP
Gemphire Therapeutics
914.87 millionN/ANot Optionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3075.46 million47.38 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 millionN/ANot Optionable
Stemline Therapeutics Inc stock logo
STML
Stemline Therapeutics
9252.51 millionN/AOptionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulcrum Therapeutics stock logo

Fulcrum Therapeutics NASDAQ:FULC

$7.84 -0.06 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$7.84 0.00 (0.00%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gemphire Therapeutics stock logo

Gemphire Therapeutics NASDAQ:GEMP

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.03 +0.00 (+15.38%)
As of 03:34 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.84 +0.07 (+3.65%)
Closing price 03:57 PM Eastern
Extended Trading
$1.82 -0.02 (-1.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Stemline Therapeutics stock logo

Stemline Therapeutics NASDAQ:STML

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.